SCHEMBL8025937

SCHEMBL8025937

CCC(C(=O)O)N1Cc2sc(-c3cccc(OCc4ccccc4)c3)cc2S1(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 2/20 0.40
MMP9 P14780 1/20 0.40
MMP1 P03956 1/20 0.40
PTPN1 P18031 1/20 0.40
MME P08473 1/20 0.40
ACE P12821 1/20 0.40
CPA1 P15085 1/20 0.40
ACE2 Q9BYF1 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
MAOB P27338 1/20 0.39
FFAR4 Q5NUL3 1/20 0.38
NR4A2 P43354 3/20 0.38
GPR132 Q9UNW8 1/20 0.38
CTSA P10619 1/20 0.37
PTGES O14684 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8017413 0.93 NR4A2 (0.44) ADAM17MMP9MMP1PTPN1MRGPRX4
SCHEMBL8027488 0.89 PPARG (0.41) ADAM17MMP9MMP1PTPN1FFAR4
SCHEMBL13786795 0.87 MAPT (0.39) MMP9MMP1KDM4EMEN1LMNA
SCHEMBL8018469 0.86 MRGPRX4 (0.41) ADAM17MMP9MMP1MRGPRX4FFAR4
SCHEMBL8028979 0.85 MAPT (0.37) MMP9MMP1KDM4EMEN1LMNA
SCHEMBL8021276 0.85 ADAM17 (0.42) ADAM17MMP9MMP1MRGPRX4MAOB
SCHEMBL13786777 0.85 S1PR5 (0.39) ADAM17MMP9MMP1MRGPRX4CTSA
SCHEMBL8027320 0.85 S1PR1 (0.38) ADAM17MMP9MMP1PTPN1FFAR4
SCHEMBL8030906 0.84 MRGPRX4 (0.41) ADAM17MMP9MMP1MRGPRX4FFAR4
SCHEMBL8027572 0.84 MMP1 (0.39) ADAM17MMP9MMP1PTPN1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192154-A1 SULTAM DERIVATIVES ASAHI KASEI PHARMA CORPORATION (JP) 2009-07-30 US disclosed
US-20090192154-A1 SULTAM DERIVATIVES ASAHI KASEI PHARMA CORPORATION (JP) 2009-07-30 US disclosed
WO-2009084501-A1 SULTAM DERIVATIVE ASAHI KASEI PHARMA CORPORATION (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192154-A1 SULTAM DERIVATIVES SULT1A1, SULT2A1, ADAMTS1 ADAM17 67/4885MMP9 19/4885MMP1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.